Bio Innovation Leaders Summit 2027
10–11 February 2027 · Berlin Palace Hotel · Invited Audience Only
Where biologics leaders define what scales next.
Leadership must keep pace to evolve and stay competitive.
AI-powered bioprocessing, agile modular capacity, viral safety & QC and downstream purification — four critical buying centers now shaping resilient biomanufacturing.
01 · BILS.ai
Bio Innovation Leaders Dialogue London 2027
The four pillars of BILS.ai
AI‑enabled bioprocessing
Why it matters: It turns AI from experimentation into a daily control lever for yield, quality and release, so decisions are driven by live process data, not by the last deviation report.
Safety Filtration
Why it matters: Where biologics leaders decide what scales safely next. AI‑powered bioprocessing, filtration‑driven agile capacity, viral safety and QC, and downstream purification built for speed, safety and purity.
Workforce and human systems
Why it matters: It ensures automation and AI amplify human expertise rather than erode it, so factories stay resilient even as technology and portfolios change.
Sustainable resilient biomanufacturing
Why it matters: It aligns cost, compliance and climate by cutting resource intensity and strengthening supply continuity, which is now a board‑level expectation, not a side benefit.
02 · THE GAP
Curated for senior biomanufacturing leaders
Why it Matters.
In 2027 AI, automation and digital bioprocessing are moving from pilots into the heart of biomanufacturing.
At the same time companies are committing record capital to new facilities and regional networks while facing tight margins, skills gaps and rising sustainability expectations.
The question is no longer whether these shifts are coming but how to deploy them without breaking cost, compliance or supply.
Cell Biology at Scale.
Three Industries.
One Question.
How Do We Turn Cells into Scalable Solutions?
03 · WHO IT'S CURATED FOR
Where biologics leaders define what scales next.
Human-centred Industry 5.0 systems. Sustainable, resilient biomanufacturing built for 2027 and beyond. The people making those decisions are in this room. Invite-only. Berlin. 10–11 February 2027.
MANUFACTURING & OPERATIONS
An invite‑only deployment room for biomanufacturing, built for senior leaders across biologics, CGT and cultivated protein who are turning AI, new capacity and sustainability goals into working plants and networks in 2027.
VP Manufacturing · COO · Production Site Director · Head of Operations Engineering
Quality & Regulatory
VP Quality · Head of QA · Chief Quality Officer · Safety · Bioprocess
It is a curated, invite‑only meeting in London for senior decision makers from biologics, cell and gene therapy who sign off the next wave of capacity, technology and partnership commitments.
MSAT & PROCESS DEVELOPMENT
Head of MSAT · VP Tech Ops · Process Development Lead
Over two days the focus stays on four pillars – AI‑enabled bioprocessing, agile capacity and networks, workforce and human systems and sustainable resilient operations – because that is where 2026 decisions are actually made.
DIGITAL, DATA & R&D
VPs Innovation · VP Digital · Head of Data Science Digital Transformation Lead · Heads of R&D · Automation · Infrastructure
For technology providers and CDMOs BILS.ai is where current bioprocess and biomanufacturing trends turn into multi‑year deployment roadmaps.
For operators it is a chance to stress‑test strategies with peers who are facing the same pressures on performance, resilience and sustainability and need answers they can put into practice in their own plants.
Advisory Circle.
Advisory & Past Speakers
For the few:
The AIO feature is for leaders willing to sign their name under AI-enabled decisions.
The AIO feature is for leaders willing to sign their name under AI-enabled decisions.
www.aiocircle.com
 |
|---|
Step into the circle. Subscribe.
Stay updated. Receive the agenda. Partner with us.
